
EliLilly has acquired AtaiBeckley for US$2.8 billion, gaining control of BPL-003, a DMT-derived nasal spray in Phase 3 trials for treatment-resistant depression with Phase 3 results expected in 2029. Read more: investingnews.com/eli-lilly-buys…

English


